The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas https://www.biorxiv.org/content/10.1101/2022.11.28.518230v1?med=mas
The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas https://www.biorxiv.org/content/10.1101/2022.11.28.518230v1?med=mas